Lacy Mills
Family · Independence, LANPI 1477873362
Payments from drug & device makers
Across 318 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$708
- AbbVie$690
- GSK$281
- Novo Nordisk$280
- Pfizer$265
- Takeda Pharmaceuticals U.S.A., Inc.$261
- plus $3K from 38 others
What the payments were for
- Food & beverage$5,289100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$5,289 in reported general payments places this provider in the 90th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 71 | $104,291 |
| OzempicSemaglutide | 48 | $55,203 |
| TrulicityDulaglutide | 29 | $31,743 |
| EliquisApixaban | 39 | $31,443 |
| JardianceEmpagliflozin | 30 | $21,835 |
| FarxigaDapagliflozin Propanediol | 11 | $12,794 |
| LinzessLinaclotide | 23 | $11,891 |
| FetzimaLevomilnacipran Hcl | 22 | $10,689 |
| VyvanseLisdexamfetamine Dimesylate | 27 | $9,830 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $9,612 |
| VascepaIcosapent Ethyl | 13 | $8,429 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $7,401 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,685 |
| SynthroidLevothyroxine Sodium | 38 | $3,728 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 105 | $3,139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $708 | $136,034100 claims |
| Novo NordiskOzempic | $280 | $55,20348 claims |
| PfizerEliquis | $265 | $31,44339 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $209 | $28,52043 claims |
| AbbVieLinzess, Fetzima, Synthroid | $690 | $26,30883 claims |
| AstraZenecaFarxiga | $242 | $12,79411 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $261 | $9,83027 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $45 | $2,186277 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,610 family providers in Louisiana.
Other family in Independence
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.